swiss pharmaceuticals bpc 157 BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers BPC 157 (Body Protection Compound-157)
Description
W., Wilson, I
Deutsch, G., Deshpande, H., Lai, H
In the first study, blinded evaluators used urodynamic and voiding parameters to rate patient improvement ("objective criteria") and patients rated global improvement ("subjective criteria")
Dual GIP/GLP-1 receptor agonist for blood sugar control and significant weight reduction
